| CAS No. | 853400-76-7 |
|---|---|
| MDL No. | N/A |
| MF | C13H21N3O6 |
| MW | 315.32 |
| InChI Key | BUSXWGRAOZQTEY-SDBXPKJASA-N |
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| 5 mg | 99% | $89 | In Stock | |
| 10 mg | 99% | $139 | In Stock | |
| 25 mg | 99% | $319 | In Stock | |
| 50 mg | 99% | $468 | In Stock | |
| 100 mg | 99% | $751 | In Stock | |
| 250 mg | 99% | $1499 | In Stock | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Trofinetide is a tripeptide composed of glycine, 2-methyl-L-proline, and L-glutamic acid linked by peptide bonds. It is the first and only FDA-approved treatment for Rett syndrome in adults and pediatric patients aged two years and older. It functions as a neuroprotective and anti-inflammatory agent. Chemically, it is a tripeptide, pyrrolidinecarboxamide, primary amino compound, secondary carboxamide, tertiary carboxamide, and dicarboxylic acid. It is functionally related to L-glutamic acid and glycine.
| CAS No. | 853400-76-7 |
|---|---|
| Product Name | Trofinetide |
